Dementia Today.net

Site updated at Wednesday, 22 June 2016

Living with Dementia

Biomarkers in cerebrospinal fluid can identify patients with Alzheimer’s disease

  • - Dementia News
  • Oct 22, 2012
  • Comments
  • Viewed: 437
Tags: | alpha-synuclein | alzheimer's disease | alzheimer's disease biomarkers | beta-amyloid |

Analysis of specific biomarkers in a cerebrospinal fluid sample can differentiate patients with Alzheimer’s disease from those with other types of dementia. The method, which is being studied by researchers at Sahlgrenska Academy, may eventually permit earlier detection of Alzheimer’s disease.

Due to the similarity of the symptoms, differentiating patients with Alzheimer’s from those with other types of dementia - or patients with Parkinson disease from those with other motor disorders - is often difficult.

Making a proper diagnosis is essential if proper treatment and medication are to commence at an early stage. A research team at Sahlgrenska Academy, University of Gothenburg, is developing a new method to differentiate patients with Alzheimer’s disease or Parkinson disease by analyzing a cerebrospinal fluid sample.

The study, led by Professor Kaj Blennow and conducted among 450 patients at Skåne University Hospital and Sahlgrenska University Hospital, involved testing five proteins that serve as biomarkers for the two diseases.

“Previous studies have shown that Alzheimer’s disease is associated with biochemical changes in specific proteins of the brain,” says Annika Öhrfelt, a researcher at Sahlgrenska Academy. “This study has found that the inclusion of a new protein can differentiate patients with Alzheimer’s disease from those with Lewy body dementia, Parkinson disease dementia and other types of dementia.”

Similarly, the biomarkers can differentiate patients with Parkinson disease from those with atypical Parkinsonian disorders.

“Additional studies are needed before the biomarkers can be used in clinical practice during the early stages of disease,” says Öhrfelt, “but these results represent an important step along the way.”
###

The article, entitled “Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients with Dementia and/or Parkinsonian Disorders,” was published by the Journal of the American Medical Association.

###

Contact:
Annika Öhrfelt, Researcher at Sahlgrenska Academy
Cell: +46 734-25 74 99
Landline: +46 31 343 24 06

FACTS ABOUT THE STUDY
The study analyzed the following proteins: beta-amyloid, tau (P-tau), alpha-synuclein and neurofilaments. Participating researchers from the University of Gothenburg: Annika Öhrfelt, Radu Constantinescu, Ulf Andreasson, Björn Holmberg, Henrik Zetterberg and Kaj Blennow.

###

Annika Öhrfelt
46-734-257-499
University of Gothenburg

Post a comment [ + Comment here + ]

There are no comments for this entry yet. [ + Comment here + ]




Comment
Your details

* Required field


Please enter the word you see in the image below:

Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.

Alzheimer’s Disease

behavioural deterioration1 - signs of parkinson's1 - parkinsons related dementia1 - aids related dementia1 - antipsychotics1 - brain inflammation1 - video game1 - niaiserie1 - bapineuzumab1 - mental faculties2 - brain tissue biopsy1 - amyloid protein1 - lrp61 - parkinson's diagnosis1 - impassable plaques1 - berrios2 - synaptic loss1 - hiv1 - hypertension and dementia1 - pocd1 - dementing illness1 - alzheimer's-related plaque1 - dsm-51 - korsakoff syndrome3 - neurotoxic oligomers1 - alcoholism1 - neuronal degeneration1 - protein alpha-synuclein1 - dimebon1 - boissier de sauvages2 -